Combinations of hcv protease inhibitor(s) and cyp3a4...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/16 (2006.01) A61K 31/192 (2006.01) A61K 31/196 (2006.01) A61K 31/343 (2006.01) A61K 31/395 (2006.01) A61K 31/40 (2006.01) A61K 31/403 (2006.01) A61K 31/427 (2006.01) A61K 31/454 (2006.01) A61K 31/496 (2006.01) A61K 31/4965 (2006.01) A61K 38/06 (2006.01) A61K 38/07 (2006.01) A61K 45/06 (2006.01) A61P 31/12 (2006.01)

Patent

CA 2647158

Disclosed are medicaments, pharmaceutical compositions, pharmaceutical kits, and methods based on combinations comprising, separately or together: (a) a CYP3A4 inhibitor; and (b) a HCV protease inhibitor; for concurrent or consecutive administration in treating a human subject infected with HCV.

La présente invention concerne des médicaments, des compositions pharmaceutiques, des kits pharmaceutiques et des méthodes reposant sur des combinaisons qui contiennent, séparément ou conjointement : (a) un inhibiteur de CYP3A4; et (b) un inhibiteur de la protéase du VHC. Lesdits médicaments, compositions pharmaceutiques et kits pharmaceutiques sont conçus pour une administration concurrente ou consécutive, aux fins de traitement d'un sujet humain atteint par le VHC.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Combinations of hcv protease inhibitor(s) and cyp3a4... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combinations of hcv protease inhibitor(s) and cyp3a4..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinations of hcv protease inhibitor(s) and cyp3a4... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1603209

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.